Coronary artery disease surveillance among childhood, adolescent and young adult cancer survivors: A systematic review and recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group

Dalen, Elvira C. van; Mulder, Renée L.; Suh, Eugene; Ehrhardt, Matthew J.; Aune, Gregory J.; Bárdi, Edit; Benson, Bradley J.; Bergler‐Klein, Jutta; Chen, Ming H.; Frey, Eva; Hennewig, Ulrike; Lockwood, Liane; Martinsson, Ulla; Muraca, Monica; Pal, Helena van der; Plummer, Chris; Scheinemann, Katrin; Schindera, Christina; Tonorezos, Emily S.; Wallace, William H.; Constine, Louis S.; Skinner, Roderick; Hudson, Melissa M.; Kremer, Leontien C. M.; Levitt, Gill; Mulrooney, Daniel A.

doi:10.1016/j.ejca.2021.06.021

Cited by 29 publications

(10 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…652 Follow-up of paediatric CS according to the International Late Effects of Childhood Cancer Guideline Harmonization Group is recommended. 653 This includes risk stratification based upon the total cumulative dose of anthracycline chemotherapy and MHD delivered (Table 11). Annual review of CVRF and education to promote a healthy lifestyle is recommended.…”

Section: In Patientsmentioning

confidence: 99%

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)

Lyon¹,

López‐Fernández²,

Couch³

et al. 2022

European Heart Journal

Self Cite

880

934

View full text Add to dashboard Cite

Coronary care unit CDK Cyclin-dependent kinase CHA 2 DS 2 -VASc Congestive heart failure, Hypertension, Age ≥ 75 years (2 points), Diabetes mellitus, Stroke (2 points)-Vascular disease, Age 65-74 years, Sex category (female) CIED Cardiac implantable electronic device CML Chronic myeloid leukaemia CMR Cardiac magnetic resonance COMPASS-CAT Prospective COmparison of Methods for thromboembolic risk assessment with clinical Perceptions and AwareneSS in real-life patients-Cancer Associated Thrombosis CPET Cardiopulmonary exercise testing CrCl Creatinine clearance CRF Cardiorespiratory fitness CRS Cytokine release syndrome CS Cancer survivors CT Computed tomography CTLA-4 Cytotoxic T lymphocyte-associated antigen-4 cTn Cardiac troponin CTRCD Cancer therapy-related cardiac dysfunction CTR-CVT Cancer therapy-related cardiovascular toxicity CV Cardiovascular CVD Cardiovascular disease CVRF Cardiovascular risk factorsData derived from a single randomized clinical trial or large non-randomized studies.Consensus of opinion of the experts and/or small studies, retrospective studies, registries.©ESC 2022 ESC Guidelines © ESC 2022This table refers to anthracycline equivalence dose using doxorubicin as a reference. Note that these isoequivalent doses are derived from paediatric CS. CS, cancer survivors; CV, cardiovascular.a Data for idarubicin are based upon an estimated anticancer efficacy ratio, not derived from cardiotoxicity data. The CV toxicity dose ratio provides the value that should be used to multiply the dose of the anthracycline of interest to convert to isoequivalent doses of doxorubicin; e.g. to convert 125 mg/m 2 of epirubicin to doxorubicin isoequivalent, multiply the dose by 0.8 (125 mg/m 2 × 0.8 = 100 mg/m 2 of doxorubicin).

show abstract

Section: In Patientsmentioning

confidence: 99%

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)

Lyon¹,

López‐Fernández²,

Couch³

et al. 2022

European Heart Journal

Self Cite

880

934

View full text Add to dashboard Cite

show abstract

“…Germline genotypes allow for the estimation of genetic risk for many diseases with a 1-time, minimally invasive DNA extraction at any time point in the life span. The addition of this low-cost genetic test (currently <$100) may fill an identified knowledge gap for surveillance of cancer survivors 43 as well as guide clinical decision making and motivate future health counseling.…”

Section: Discussionmentioning

confidence: 99%

Contribution of Genome-Wide Polygenic Score to Risk of Coronary Artery Disease in Childhood Cancer Survivors

Sapkota

Liu²,

Li³

et al. 2022

JACC: CardioOncology

Self Cite

View full text Add to dashboard Cite

“…Therefore, a longterm survivor surveillance strategy is required to identify those at high risk of developing late effects, particularly patients who have received high-dose doxorubicin and prior radiation. 9 Cardiac rehabilitation for those who have functional deterioration is also important.…”

Section: Follow-up Of Long-term Survivors After Therapy: Late Effectsmentioning

confidence: 99%

Essentials of cardio-oncology

Ferreira¹,

Ghosh²

2023

Clinical Medicine

View full text Add to dashboard Cite

Cardio-oncology is a subspecialty that provides cardiac care for patients with cancer. Newer oncological agents have not only increased survivorship, but also sprouted novel cardiovascular toxicity (CVT) involving any component of the cardiovascular system, albeit with some preferential targets. Patients with cancer should undergo a baseline cardiovascular risk assessment and have individualised surveillance planned during cancer therapy and post treatment. The early diagnosis of CVT, by clinical history and examination along with imaging and laboratory analysis, is paramount. Management includes cardioprotective strategies and multidisciplinary decision-making regarding the risk-benefit ratio of oncological treatment based on CVT. Cardio-oncology patient clinical trajectory Baseline cardiovascular risk stratification assessmentBaseline clinical assessment for cardiovascular risk factors, history of antecedent CVD and cardiotoxic therapies, physical

show abstract

Coronary artery disease surveillance among childhood, adolescent and young adult cancer survivors: A systematic review and recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group

Cited by 29 publications

References 46 publications

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)

Contribution of Genome-Wide Polygenic Score to Risk of Coronary Artery Disease in Childhood Cancer Survivors

Essentials of cardio-oncology

Contact Info

Product

Resources

About